BioSpace News Archive

NeuroMetrix, Inc. announced that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, will be presenting at the H.C. Wainwright BioConnect Conference to be held virtually on January 10-13, 2022.

PacBio, a leading provider of high-quality, long-read sequencing platforms, and the Care4Rare Canada Consortium (Care4Rare) announce today they are collaborating to study some of the most complex unexplained rare disease cases within Canada.

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will present at the H.C. Wainwright Virtual BIOCONNECT Conference being held January 10-13, 2022.

Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced enrollment of the first patient in the COSIRA-II clinical trial. COSIRA-II (COronary SInus Reducer for the Treatment of Refractory Angina) is a pivotal trial that will study the Neovasc Reducer™ (“Reducer”), designed to reduce angina symptoms in patients with refractory angina.

Sonoma Pharmaceuticals, Inc. announced that it will be featured as a presenting company at the H.C. Wainwright BioConnect Conference.

COPAN Diagnostics is proud to announce the FDA clearance of Colibri™, an automated processor that is a complementary part of WASPLab®, COPAN’s full laboratory automation system.

Scorpion Therapeutics, Inc. has been selected by BioSpace to join its NextGen Bio “Class of 2022.” The recognition from BioSpace, a life sciences industry news outlet and career hub, highlights top up-and-coming biopharmaceutical companies to watch in the new year.

Buntanetap, previously known as ANVS401 or Posiphen, is sometimes mistaken for phenserine.

Median Technologies (ALMDT:PA) announces outstanding performance for its iBiopsy® Lung Cancer Screening (LCS) CADe algorithm in detecting potentially cancerous lung nodules.

Invenra, Inc., a biotechnology company focused on the discovery and development of multispecific antibodies for immuno-oncology, today announced the appointment of Daniel S. Pereira, Ph.D., as Chief Scientific Officer.